OptraSCAN wins FDA clearance for integrated digital pathology system

OptraSCAN, Inc. said July 9, 2026, that the U.S. Food and Drug Administration cleared its OptraSCAN System under 510(k) K260755. The clearance covers the OS-Ultra Scanner, ImagePath software and HER2 Image Analysis, giving the company a regulatory green light for a bundled digital pathology platform.

Why it matters: - The FDA clearance gives OptraSCAN a regulatory milestone for a full digital pathology workflow, not just a standalone scanner. - The system combines whole-slide imaging and HER2 Image Analysis, which can support labs looking for faster, more scalable diagnostic workflows. - OptraSCAN is positioning the clearance as part of a lower-cost deployment model for hospitals, reference labs and research institutions.

What happened: - OptraSCAN said July 9, 2026, that the FDA cleared the OptraSCAN System through 510(k) clearance K260755. - The clearance covers an integrated system that includes the OS-Ultra Scanner, a color display monitor and a workstation running ImagePath image management software. - The cleared system also includes HER2 Image Analysis Software.

The details: - OptraSCAN described the cleared offering as an integrated platform for digital pathology and image analysis. - Devika Gholap, Chief Product Officer, said the clearance strengthens OptraSCAN’s mission to make digital pathology affordable through a pay-per-use model. - Gholap said digital images from the OS-Ultra Scanner can be evaluated at a fraction of conventional costs and without upfront capital investment through OptraSCAN’s Digital Lab as a service model. - Gholap said OptraSCAN systems are being deployed across laboratories nationally. - Dr. Jiaoti Huang, Chair of OptraSCAN’s Medical Advisory Board and Chair of the Department of Pathology at Duke University, said the system combines high-quality whole-slide imaging with validated HER2 image analysis. - Huang said the platform is designed to support efficiency and diagnostic confidence. - OptraSCAN said the clearance helps make digital pathology accessible, scalable and economically sustainable for institutions of every size. - The company said its broader portfolio includes whole slide scanners, image management software, image analysis, telepathology and workflow automation tools. - OptraSCAN said its applications span routine histopathology, oncology, cytology, infectious diseases and translational research. - OptraSCAN said it has 165+ global installations across hospitals, reference laboratories, research institutions and life sciences organizations in 30+ countries. - The company is headquartered in California and focuses on on-demand digital pathology.

Between the lines: - The clearance signals OptraSCAN’s move from a product pitch to a regulated platform sale, which can matter for lab buyers that want bundled hardware, software and analysis tools. - The pay-per-use framing suggests OptraSCAN is targeting labs that want digital pathology without the upfront cost of a traditional purchase model. - The HER2 feature points to oncology use cases, where validated image analysis can help standardize review workflows.

What's next: - OptraSCAN is likely to use the clearance to expand deployments in U.S. laboratories. - The company also appears to be leaning on the clearance to support broader adoption of its Digital Lab as a service model. - Labs evaluating digital pathology platforms now have an FDA-cleared option that includes scanner, software and HER2 analysis in one system.

The bottom line: - OptraSCAN has turned an FDA 510(k) clearance into a broader commercial push for affordable, scalable digital pathology.